Modelling the long QT syndrome with induced pluripotent stem cells

Nature

Volumn 471, Issue 7337, 2011, Pages 225-230

  Itzhaki, Ilanit ^a   Maizels, Leonid ^a   Huber, Irit ^a   Zwi Dantsis, Limor ^a   Caspi, Oren ^a   Winterstern, Aaron ^a   Feldman, Oren ^a   Gepstein, Amira ^a   Arbel, Gil ^a   Hammerman, Haim ^b   Boulos, Monther ^b   Gepstein, Lior ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PROTEIN KCNH2; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

CELL ORGANELLE; DISEASE PREVALENCE; ELECTRODE; GENE EXPRESSION; GENETIC ANALYSIS; ION; MUTATION; NUMERICAL MODEL; OPTIMIZATION; PARADIGM SHIFT; PHENOTYPE; POTASSIUM; SODIUM;

ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DISEASE ACTIVITY; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LONG QT SYNDROME; MISSENSE MUTATION; PATCH CLAMP; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; WHOLE CELL;

ADULT; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; EMBRYONIC STEM CELLS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FIBROBLASTS; HUMANS; INDIVIDUALIZED MEDICINE; INDUCED PLURIPOTENT STEM CELLS; LONG QT SYNDROME; MODELS, BIOLOGICAL; MUTATION, MISSENSE; MYOCYTES, CARDIAC; NUCLEAR REPROGRAMMING; PATCH-CLAMP TECHNIQUES; PHENOTYPE;

EID: 79952446402     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09747     Document Type: Article

References (28)

1. Park, I.H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877-886 (2008).
2. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007). (Pubitemid 350138099)
3. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
4. Kiskinis, E. & Eggan, K. Progress toward the clinical application of patient-specific pluripotent stem cells. J. Clin. Invest. 120, 51-59 (2010).
5. Goldenberg, I. & Moss, A.J. Long QTsyndrome. J.Am. Coll. Cardiol. 51, 2291-2300 (2008).
6. Sanguinetti, M. C. & Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 440, 463-469 (2006).
7. Marbán, E. Cardiac channelopathies. Nature 415, 213-218 (2002). (Pubitemid 34059527)
8. Tenenbaum, M. et al. Identification of the gene causing long QT syndrome in an Israeli family. Isr. Med. Assoc. J. 10, 809-811 (2008).
9. Nakajima, T.et al. Novel mechanismofHERG current suppressioninLQT2: shift in voltage dependence of HERG inactivation. Circ. Res. 83, 415-422 (1998). (Pubitemid 28389971)
10. He, J. Q., Ma, Y., Lee, Y., Thomson, J. A. & Kamp, T. J. Human embryonic stem cells develop into multiple typesof cardiac myocytes: action potential characterization. Circ. Res. 93, 32-39 (2003). (Pubitemid 36859038)
11. Kehat, I. et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108, 407-414 (2001). (Pubitemid 32730787)
12. Zhang, J. et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 104, e30-e41 (2009).
13. Zwi, L. et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 120, 1513-1523 (2009).
14. 1 current in human ventricular myocytes. Circ. Res. 78, 689-696 (1996). (Pubitemid 26106881)
15. Caspi, O. et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 18, 161-172 (2009).
16. Luo, S., Michler, K., Johnston, P. & Macfarlane, P. W. A comparison of commonly used QT correction formulae: the effectof heart rate on the QTc ofnormal ECGs. J. Electrocardiol. 37 (suppl. 1), 81-90 (2004). (Pubitemid 39452873)
17. Halbach, M., Egert, U., Hescheler, J. & Banach, K. Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell. Physiol. Biochem. 13, 271-284 (2003). (Pubitemid 37356733)
18. 21 current. Circ. Res. 64, 977-990 (1989). (Pubitemid 19117651)
19. Patel, C. & Antzelevitch, C. Pharmacological approachtothe treatmentof long and short QT syndromes. Pharmacol. Ther. 118, 138-151 (2008).
20. Fermini, B. & Fossa, A. A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev. Drug Discov. 2, 439-447 (2003). (Pubitemid 37361725)
21. Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910 (2004). (Pubitemid 39136212)
22. 1 current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J. Am. Coll. Cardiol. 55, 801-809 (2010).
23. Moretti, A. et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397-1409 (2010).
24. Huangfu, D. et al. Induction of pluripotent stem cells by defined factors is greatly improvedbysmall-molecule compounds.NatureBiotechnol.26, 795-797 (2008). (Pubitemid 351961456)
25. Lowry, W.E.et al.Generationofhumaninducedpluripotentstemcellsfromdermal fibroblasts. Proc. Natl Acad. Sci. USA 105, 2883-2888 (2008).
26. Arbel, G. et al. Methods for human embryonic stem cells derived cardiomyocytes cultivation, genetic manipulation, and transplantation. Methods Mol. Biol. 660, 85-95 (2010).
27. Park, I. H. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141-146 (2008).
28. Kehat, I., Gepstein, A., Spira, A., Itskovitz-Eldor, J. & Gepstein, L. High-resolution electrophysiological assessment of human embryonic stem cell-derived cardiomyocytes: a novel in vitro model for the study of conduction. Circ. Res. 91, 659-661 (2002). (Pubitemid 35204947)